AU2021319051A1 - GLP-1 receptor antagonists - Google Patents

GLP-1 receptor antagonists Download PDF

Info

Publication number
AU2021319051A1
AU2021319051A1 AU2021319051A AU2021319051A AU2021319051A1 AU 2021319051 A1 AU2021319051 A1 AU 2021319051A1 AU 2021319051 A AU2021319051 A AU 2021319051A AU 2021319051 A AU2021319051 A AU 2021319051A AU 2021319051 A1 AU2021319051 A1 AU 2021319051A1
Authority
AU
Australia
Prior art keywords
compound according
syndrome
ser
lysr
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021319051A
Other languages
English (en)
Inventor
Giles Albert Brown
Miles Stuart Congreve
Conor SCULLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2021319051A1 publication Critical patent/AU2021319051A1/en
Assigned to NXERA PHARMA UK LIMITED reassignment NXERA PHARMA UK LIMITED Amend patent request/document other than specification (104) Assignors: HEPTARES THERAPEUTICS LIMITED
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021319051A 2020-07-27 2021-07-27 GLP-1 receptor antagonists Pending AU2021319051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2011604.2 2020-07-27
GBGB2011604.2A GB202011604D0 (en) 2020-07-27 2020-07-27 GLP-1 receptor antagonists
PCT/GB2021/051921 WO2022023723A1 (en) 2020-07-27 2021-07-27 Glp-1 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2021319051A1 true AU2021319051A1 (en) 2023-03-16

Family

ID=72339360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021319051A Pending AU2021319051A1 (en) 2020-07-27 2021-07-27 GLP-1 receptor antagonists

Country Status (8)

Country Link
US (1) US20230279053A1 (https=)
EP (1) EP4188409A1 (https=)
JP (1) JP2023535476A (https=)
CN (1) CN116171283A (https=)
AU (1) AU2021319051A1 (https=)
CA (1) CA3190422A1 (https=)
GB (1) GB202011604D0 (https=)
WO (1) WO2022023723A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist

Also Published As

Publication number Publication date
GB202011604D0 (en) 2020-09-09
US20230279053A1 (en) 2023-09-07
CA3190422A1 (en) 2022-02-03
CN116171283A (zh) 2023-05-26
EP4188409A1 (en) 2023-06-07
WO2022023723A1 (en) 2022-02-03
JP2023535476A (ja) 2023-08-17

Similar Documents

Publication Publication Date Title
US20250368709A1 (en) Glp-1 receptor antagonists
CN114349828B (zh) Glp-1/胰高血糖素受体双重激动剂及其应用
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
CN102821779B (zh) 新型肽及其制备方法和应用
TW201427992A (zh) 作為雙重ｇｌｐ１／升糖素激動劑之艾塞那肽－４衍生物
CN116143884B (zh) 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
WO2024149080A1 (zh) 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
AU2021319051A1 (en) GLP-1 receptor antagonists
US20230295260A1 (en) Glp receptor agonists
CN115873096B (zh) 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用
CN115960258B (zh) 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
CN117417430A (zh) 一类对glp-1和胰高血糖素受体具有激动活性的牛蛙glp-1类似物及其应用
EP4121094A1 (en) Oral glp receptor agonists
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
WO2026073030A1 (en) Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NXERA PHARMA UK LIMITED

Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED